Parkinsonian Disorders Clinical Trial
Official title:
Effect of Motor Function, Depression and Sleep Quality on Attention in Parkinson's Disease
Our study was planned to analyze motor function, endurance and sleep attention information in Parkinson's patients with detailed and objective measurements.
Parkinson's Disease (PD) is a neurodegenerative disease that occurs with the loss of dopaminergic neurons in the basal ganglia (BG) and subsequently affects multiple brain regions. There are studies that evaluate executive functions rather than cognitive functions in Parkinson's patients. However, objective evaluations of the attention parameter are quite rare. Accordingly, our study was planned to examine the effects of motor function, depression and sleep on attention in Parkinson's patients with detailed and objective measurements. Parkinson's patients (n=27) and healthy controls (n=27) aged between 40-85 will be included in the study. Balance evaluation of the individuals participating in the study was carried out by functional reaching test, one-leg standing test and Berg balance scale; Endurance with a 30-second sit-and-stand test; reaction time; with mobile application; muscle strength by hand dynamometer; functional mobility with time up and go test; walking speed, with 10 m walk test; attention with the P300 device; depression, with the Beck depression scale; Sleep quality will be assessed with the Pittsburg sleep questionnaire. At the end of the study, the effects of motor functions, sleep and depression on attention will be examined and compared with healthy controls. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
| Completed |
NCT04704349 -
Latest Imaging SPECT System Evaluation Phase 1
|
N/A | |
| Recruiting |
NCT03649503 -
The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China
|
||
| Completed |
NCT01385592 -
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
|
Phase 2 | |
| Completed |
NCT05608915 -
External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait
|
N/A | |
| Recruiting |
NCT04871464 -
Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease
|
Phase 4 | |
| Withdrawn |
NCT04847609 -
GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders
|
||
| Completed |
NCT05356845 -
Oral Health, Orofacial Function and Oral Health Care in Patients With Parkinson's Disease
|
||
| Completed |
NCT02021903 -
Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies
|
N/A | |
| Completed |
NCT03065192 -
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
|
Phase 1 | |
| Not yet recruiting |
NCT04727658 -
Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL)
|
Phase 2 | |
| Recruiting |
NCT02696603 -
Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)
|
N/A | |
| Completed |
NCT01491932 -
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
|
Phase 2 | |
| Recruiting |
NCT05906719 -
Machine Vision Based MDS-UPDRS III Machine Rating
|
||
| Completed |
NCT03156647 -
Alpha-synuclein Level in Saliva to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome
|
||
| Recruiting |
NCT02994719 -
Gait Analysis in Neurological Disease
|
||
| Completed |
NCT04974034 -
Movement Disorders Analysis Using a Deep Learning Approach
|
||
| Terminated |
NCT00686699 -
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
|
Phase 2 | |
| Completed |
NCT04925622 -
Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
|
||
| Recruiting |
NCT06193252 -
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands
|
N/A |